---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABTECT maintenance"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABTECT maintenance. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 75 evidence topics quoted from 13 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abtect-maintenance"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABTECT maintenance

<a id="heading-3.1.3"></a>

## 3.1.3 ABTECT Maintenance

<a id="heading-3.1.3.1"></a>

### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

#### Objective in the UEG Week 2026 maintenance presentation

> “Assess obefazimod efficacy and safety vs. placebo in patients with moderately to severely active UC who responded to obefazimod induction after 52 weeks of treatment overall”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.1-2"></a>

#### Objective of the subgroup presentation by prior advanced therapy response

> “Assess obefazimod efficacy and safety vs. placebo in UC patients who responded to obefazimod induction ± prior inadequate response to advanced therapies (AT-IR) at Week 52”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.1-3"></a>

#### Purpose and primary objectives of Part 1 and Part 2 in the ClinicalTrials.gov record

> “This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].”
> “This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106.”
> “The Part 1 primary objective is to compare the efficacy of ABX464 versus placebo on the proportion of subjects in clinical remission [SFS = 0 or 1, RBS = 0 and endoscopy sub-score = 0 or 1] at Week 44.”
> “The Part 2 primary objective is safety”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.1-4"></a>

#### Main objectives of Part 1, Part 2, and the long-term extension in the EU register

> “Part 1 (44 weeks): -To compare the efficacy of obefazimod versus placebo on endoscopic improvement and symptomatic remission.”
> “Part 2 (44 weeks): -To assess the safety and tolerability of obefazimod 50 mg and 25 mg at Week 44.”
> “Long-Term Extension(4 years): -To evaluate the long-term safety and tolerability of obefazimod.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.2"></a>

### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

#### Study dates and number of locations in the ClinicalTrials.gov record

> “Study Start (Actual) 2023-01-16”
> “Primary Completion (Actual) 2026-04-28”
> “Study Completion (Estimated) 2030-05”
> “This study has 413 locations”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.2-2"></a>

#### Countries, sites, and trial duration in the EU register

> “Trial duration 29 Aug 2023 → ongoing”
> “Locations 18 EU/EEA countries · 184 sites”
> “Rest of the world Mexico, Brazil, New Zealand, United Kingdom, China, Turkey, Israel, Korea, Republic of, Switzerland, Australia, Argentina, Bosnia and Herzegovina, Ukraine, United States, India, Japan, Serbia, Canada”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.2-3"></a>

#### Phase 3 program: 36 countries and over 600 sites, first U.S. participant in October 2022

> “These pivotal Phase 3 clinical trials consist of two induction trials (ABTECT-1 and ABTECT-2) and the subsequent ABTECT maintenance trial investigating obefazimod at doses of 25 mg and 50 mg across 36 countries in North America, Latin America, Europe and Asia Pacific, involving 1,275 moderately to severely active UC patients in over 600 sites.”
> “Enrollment of the first patient under this program in the United States occurred on October 11, 2022.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.3.2-4"></a>

#### Part 1 topline results announced June 1, 2026

> “PARIS, France – June 1, 2026 – 10:05 pm CEST”
> “today announced positive topline results from the Phase 3 ABTECT maintenance trial evaluating obefazimod”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.2-5"></a>

#### Part 2 topline results announced June 29, 2026

> “PARIS, France – June 29, 2026 – 10:05 pm CEST”
> “today announced topline results from ABTECT Maintenance Part 2, the supplemental portion of its Phase 3 UC maintenance program”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.2-6"></a>

#### Presentation at UEG Week 2026 in Barcelona

> “taking place October 17–20, 2026, in Barcelona, Spain”
> “Efficacy and safety of obefazimod in patients with moderately to severely active ulcerative colitis: results from the Phase 3, randomized, double-blind, placebo-controlled, 44-week maintenance trial (ABTECT-Maintenance)”
> “Efficacy of obefazimod in Phase 3 ABTECT-Maintenance trial: results of 44-week therapy in subsets of patients with and without prior inadequate response to advanced therapies”

Source: [Abivax press release, UEG Week 2026 presentations (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-present-data-obefazimod-united-european-gastroenterology)

<a id="heading-3.1.3.3"></a>

### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

#### Official title and design details in the ClinicalTrials.gov record

> “A Randomized, Double-blind, Multicenter Phase III Study to Evaluate the Long-term Efficacy and Safety of ABX464 25 mg or 50 mg Once Daily as a Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis”
> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Parallel Assignment”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.3-2"></a>

#### Two treatment phases: a 44-week maintenance phase (Part 1 and Part 2) and a 4-year long-term extension

> “This study consists of a 44-week maintenance treatment phase (Part 1 and Part 2), followed by a 4-year Long Term Extension (LTE) treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.”
> “The maintenance phase is a 44-week double blind, placebo-controlled, phase. Subjects who are clinical responders after 8 weeks induction will be randomized to Part 1, and those who are non-clinical responders will be randomized to Part 2.”
> “At the end of the 44-week maintenance phase, subjects will continue their allocated treatment until the maintenance phase is unblinded.”
> “Once the study is unblinded, all subjects receiving obefazimod will continue their allocated treatment. Subjects receiving placebo will be allocated to obefazimod 25 mg or can terminate the study.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.3-3"></a>

#### Randomization by induction treatment and response status

> “Among both induction studies, subjects assessed as responders will be randomized as follows into Part 1 of the maintenance study according to their induction treatment: ABX464 Dose 50 mg QD ABX464 Dose 25 mg QD Placebo. All subjects with clinical response who were dosed with placebo in the induction studies will be randomized into the placebo group.”
> “Among both induction studies, subjects assessed as non-responders will be randomized as follows into Part 2 of the maintenance study according to their induction treatment: ABX464 Dose 50 mg QD (all subjects who received 50 mg in induction) ABX464 Dose 25 mg QD (all subjects who received 25 mg in induction) Subjects who were allocated to placebo in the induction study will be randomized to obefazimod 50 mg or 25 mg in a blinded manner.”
> “All eligible subjects will be randomized to either the double blind, placebo-controlled Part #1 (ABX464 50mg or 25mg or placebo) or randomized to double-blind Part #2 (ABX464 50mg or 25mg) depending on their clinical response at the end of induction.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.3-4"></a>

#### Part 1: re-randomization of obefazimod induction responders to 25 mg, 50 mg, or placebo

> “The Phase 3 ABTECT maintenance trial is a global 44-week multicenter, randomized, double-blind, placebo-controlled trial that evaluated the long-term efficacy and safety of obefazimod at 25 mg and 50 mg administered orally once-daily in adults with moderately to severely active UC. Participants who were clinical responders after the 8-week ABTECT-1 and ABTECT-2 induction trials (N=580) were re-randomized to receive 25 mg obefazimod, 50 mg obefazimod, or placebo.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.3-5"></a>

#### Responder definition, stratification factors, and placebo induction responders

> “ABTECT Phase 3 Responder Re-Randomized Maintenance Trial Design”
> “Induction Clinical Response defined as decrease in the MMS ≥ 2 points and ≥30% from baseline, with a decrease in RBS ≥ 1 or an absolute RBS ≤ 1”
> “Randomization stratification factors: clinical remission at maintenance baseline (yes/no), induction treatment (25 mg/50 mg), and maintenance baseline oral corticosteroids usage (yes/no)”
> “Placebo induction responders were maintained on blinded placebo in maintenance”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.3-6"></a>

#### Part 2: induction non-responders and Part 1 relapsers

> “Part 2 of the Phase 3 Maintenance trial enrolled patients who either did not achieve clinical response following induction treatment or who experienced disease relapse during the re-randomized maintenance trial (Part 1), expanding both the efficacy and safety results in a more refractory patient population than the registrational maintenance cohort.”
> “Patients who achieved clinical response with obefazimod during induction and relapsed after being re-randomized to placebo in Part 1 of the maintenance trial were treated with open-label 50 mg obefazimod”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.3-7"></a>

#### Central endoscopy reading and primary endpoint at the end of the 44-week maintenance trial (52 weeks in total)

> “Each of the trials were randomized, double-blind and placebo-controlled, using independent and central review of the video-taped endoscopies with the primary endpoint of clinical remission according to the Modified Mayo Score assessed at week 8 (induction) and at the end of the 44-week maintenance trial (total 52 weeks), as recommended by the FDA.”
> “After week 44, a long-term extension trial will follow for eligible and willing subjects for an additional for up to 4 years, or until the commercialization of obefazimod, whichever occurs first.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="heading-3.1.3.4"></a>

### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

#### Inclusion criteria for the maintenance phase in the ClinicalTrials.gov record

> “Subjects must have completed the induction treatment study (ABX464-105 or ABX464-106), and patients' clinical response status must be available.”
> “Subjects with a valid endoscopy performed at the end of the induction study and results from central reader available at Day 1.”
> “16 Years and older”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.4-2"></a>

#### Exclusion criteria for the maintenance phase in the ClinicalTrials.gov record

> “Subjects who permanently discontinued the study treatment during the induction study (either ABX464-105 or ABX464-106).”
> “Subjects who have developed any major illness/condition (eg. primary sclerosis cholangitis, Crohn's disease, colectomy, diverting ileostomy, colon cancer or colonic adenomas [low or high grade dysplasia]).”
> “Subjects with evidence of an unstable clinical condition (eg. toxic megacolon, fulminant colitis, bowel perforation, uncontrolled ischemic disease, congestive heart failure with NYHA class 3 or 4 symptoms) during the induction study that, in the investigator's judgment, will substantially increase the risk to the subject if he or she participates in the study.”
> “Male or female planning a pregnancy, or pregnant female subjects”
> “Introduction during induction study of prohibited medications, dosages, surgical or non-medicinal procedures indicated for UC (except antidiarrheals and motility agents for acute diarrhea).”
> “Subject who is planning to receive live vaccine during the study.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.4-3"></a>

#### Minimum age of 16 years, or 18 years in the EU/EEA, Israel, Serbia, and Ukraine

> “Male or female (at birth) at least 16 years old, except in EU/EEA, Israel, Serbia and Ukraine, where subjects must be at least 18 years old at the time of eligibility assessment. Where enrolment of adolescents is allowed, adolescent subjects must weigh > 40 kg and meet the definition of Tanner stage 5 at screening.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.4-4"></a>

#### Long-term extension entry criteria

> “Subject must have completed the maintenance phase”
> “Investigator and subject must assess and agree that the subject has received, and will continue to receive benefit from being in the study”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="heading-3.1.3.5"></a>

### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

#### Oral dosing once daily with food for 44 weeks

> “Subjects will be orally dosed during 44 weeks”
> “Administered once daily, preferably in the morning, with food”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.5-2"></a>

#### Long-term extension: continued allocated treatment for up to 4 years

> “At the end of the maintenance phase (week 44), subjects can continue their allocated treatment for up to 4 years. Once the maintenance phase is unblinded, subjects receiving placebo in the maintenance phase will be allocated to obefazimod 25 mg or can terminate the study.”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.5-3"></a>

#### Investigational products: 25 mg and 50 mg hard capsules and matching placebo

> “Pharmaceutical form CAPSULE, HARD”
> “Maximum daily dose 25 mg milligram(s) Maximum total dose 7700 mg milligram(s) Maximum duration of treatment 44 week(s)”
> “Maximum daily dose 50 mg milligram(s) Maximum total dose 15400 mg milligram(s) Maximum duration of treatment 44 week(s)”
> “The placebo for the 25 and 50 mg ABX464 hard capsules.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.5-4"></a>

#### Dose escalation to open-label 50 mg after relapse in Part 1

> “Among patients who relapsed during Maintenance Part 1, re-treatment with 50 mg obefazimod resulted in clinically meaningful rates of clinical remission, clinical response, endoscopic improvement, HEMI and endoscopic remission by Week 44.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="heading-3.1.3.6"></a>

### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

#### 3.1.3.6.1 Rationale for Using Clinical Remission by Modified Mayo Score as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

##### FDA recommendation: proportion in clinical remission by the modified Mayo Score as the primary endpoint

> “We recommend evaluating the proportion of subjects achieving clinical remission as the”
> “primary endpoint.”
> “Clinical remission: Defined as an mMS score of 0 to 2, including the following three”
> “Stool frequency subscore = 0 or 1”
> “Rectal bleeding subscore = 0”
> “Centrally read endoscopy subscore = 0 or 1 (score of 1 modified to”
> “exclude friability)”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.3.6.1-2"></a>

##### FDA recommendation: induction followed by randomized withdrawal maintenance with evaluation at about 52 weeks

> “One approach (induction followed by randomized withdrawal maintenance) is to”
> “receive either active treatment or placebo, and efficacy is evaluated again at the end”
> “of the maintenance phase (e.g., 52 weeks).”
> “Placebo responders at the end of induction should continue to receive blinded placebo in maintenance.”
> “Although clinical response is not the final treatment goal, this definition may be used as a criterion at the end of induction to rerandomize subjects who are demonstrating improvement to continue into a maintenance phase in the induction/maintenance design.”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.3.6.1-3"></a>

##### FDA recommendation: remission in participants entering maintenance in remission to show durability

> “induction phase are rerandomized in the maintenance phase, we recommend that”
> “sponsors assess remission within the subset of subjects who enter the maintenance”
> “phase in remission to support the ability of the therapy to maintain a durable state”

Source: [FDA draft guidance, ulcerative colitis drug development (2022)](https://www.fda.gov/media/158016/download)

<a id="topic-3.1.3.6.1-4"></a>

##### Company definition of the primary endpoint and its basis in FDA guidance

> “The primary endpoint for induction and maintenance is clinical remission defined as SFS of 0 or 1 and not greater than baseline and RBS = 0 and endoscopy subscore of 0 or 1.”
> “At week 44 of the maintenance trial, secondary endpoints include endoscopic improvement, symptomatic remission, corticosteroid-free clinical remission, sustained clinical”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-3.1.3.6.1-5"></a>

##### Primary endpoint and key secondary endpoints as presented at UEG Week 2026

> “Primary Endpoint Clinical Remission at Week 52”
> “Defined as SFS = 0 or 1 and RBS = 0, and MES = 0 or 1 (MES of 1 modified to exclude friability)”
> “Secondary Endpoints (Week 52)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.6.1-6"></a>

##### Definitions of the key secondary endpoints in the topline release

> “Clinical remission is defined as SFS = 0 or 1, and RBS = 0 and MES = 0 or 1; Endoscopic improvement is defined as MES = 0 or 1; Endoscopic remission is defined as MES = 0; HEMI is defined as MES = 0 or 1 and Geboes Index score <3.1; Corticosteroid-free clinical remission is defined as clinical remission (SFS = 0 or 1 and RBS = 0 and MES = 0 or 1) at Week 44 and corticosteroid free for at least 12 weeks immediately prior to Week 44; Sustained clinical remission is defined as clinical remission at Week 44 in the sub-population of subjects in clinical remission at Week 8 of the induction trial”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.6.1-7"></a>

##### Corticosteroid-free clinical remission: registered in the subpopulation receiving corticosteroids at maintenance entry

> “To compare the efficacy of ABX464 versus placebo on corticosteroid-free clinical remission (clinical remission at Week 44 and corticosteroid free for at least 12 weeks prior to Week 44 in the subpopulation with corticosteroids at maintenance study entry)”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.6.1-8"></a>

##### EU register: endoscopic improvement and symptomatic remission as Part 1 primary endpoints, clinical remission as a secondary endpoint

> “Part 1 (44 weeks): Proportion of subjects who achieve endoscopic improvement at Week 44.”
> “Part 1 (44 weeks): Proportion of subjects with symptomatic remission at Week 44.”
> “Part 1: Proportion of subjects who achieve clinical remission at Week 44.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.7"></a>

### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

#### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

##### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 1116”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

<a id="topic-3.1.3.7.1-2"></a>

##### Planned participants in the EU register

> “Participants planned 1,241”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="topic-3.1.3.7.1-3"></a>

##### Induction responders entering Part 1: 678 of 1,275

> “Among the 1,275 patients randomized in the induction trials, 678 achieved clinical response and enrolled into part 1 of the maintenance trial.”

Source: [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

<a id="topic-3.1.3.7.1-4"></a>

##### Part 1 analysis population: 580 obefazimod induction responders

| Group | Participants |
| --- | --- |
| Obefazimod induction responders | “Obefazimod Induction Responders (n=580)” |
| Placebo | “Placebo (n=192)” |
| Obefazimod 25 mg | “25 mg (n=193)” |
| Obefazimod 50 mg | “50 mg (n=195)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.7.1-5"></a>

##### Part 2 induction non-responders and Part 1 relapsers analyzed for efficacy

> “Part 2 Induction Non-Responders – Exploratory Endpoints”
> “Part 1 Relapsers – Exploratory Endpoints”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

| Group | Participants |
| --- | --- |
| Induction non-responders, obefazimod 25 mg | “(N=81)” |
| Induction non-responders, obefazimod 50 mg | “(N=148)” |
| Part 1 relapsers, placebo then obefazimod 50 mg | “(N=109)” |
| Part 1 relapsers, obefazimod 25 mg then 50 mg | “(N=33)” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.7.1-6"></a>

##### Part 2 safety population: 186 participants on 25 mg and 447 on 50 mg

> “Includes combined induction non-responders on 50 mg in Part 2 (N=251) and Part 1 relapsers (N=196) who entered Part 2.”

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="heading-3.1.3.7.2"></a>

#### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

##### Treatment differences: Mantel-Haenszel common risk difference adjusted for the stratification factors

> “% Difference is for obefazimod minus placebo and is based on estimated common risk difference using the Mantel-Haenszel weights adjusting for the randomization stratification factors: clinical remission at maintenance baseline (yes/no), induction treatment (25 mg/50 mg), and maintenance baseline oral corticosteroids usage (yes/no)”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.7.2-2"></a>

##### Multiplicity control of the key secondary endpoints

> “Both obefazimod doses met all multiplicity-controlled key secondary endpoints (all p<0.0001)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.7.2-3"></a>

##### Subgroup analyses by prior advanced therapy response: unadjusted differences and nominal p-values

> “Deltas are unadjusted numerical difference vs placebo (percentage points); not a Mantel-Haenszel stratified estimate.”
> “P-values are nominal and have not been adjusted for multiplicity; therefore, they should be interpreted as descriptive rather than confirmatory.”
> “Δ24% for 25mg in Sustained Clinical Remission endpoint only is based on the unadjusted numerical difference vs placebo (percentage points); not a Mantel-Haenszel stratified estimate. If the Mantel-Haenzel weights is used as described above for this dose and this endpoint, the delta becomes 8% due to the small sample size (n=15).”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.7.2-4"></a>

##### Part 2 and integrated safety analyses: post-hoc, exposure-adjusted

> “The integrated post-hoc analyses presented today include the new Part 2 results, the combined Phase 3 maintenance program, and the broader Phase 2 and Phase 3 clinical development program.”
> “The post-hoc analyses below are presented progressively, from the combined Phase 2 and Phase 3 UC programs to the Phase 3 maintenance dataset (Part 1 + Part 2), and then to the Part 2 maintenance dataset, to illustrate how increasing cumulative patient-years strengthens the overall safety assessment.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="heading-3.1.3.8"></a>

### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

#### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

##### Week 44 completion without relapse or treatment switch, by group

| Measure | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| Study participants | “192” | “193” | “195” |
| Week 44 completion rate | “66 (34.3%)” | “152 (78.8%)” | “160 (82.1%)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “Completion without relapse or treatment switch”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.1-2"></a>

##### Completion of the 44-week maintenance phase at the December 2025 data safety monitoring board review

> “The ABTECT Phase 3 DSMB meeting occurred on December 18, 2025, and reported no new safety signals with over 80% of participants having completed the 44-week double blind maintenance phase of the trial.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-3.1.3.8.1-3"></a>

##### Completion of the 44-week treatment period at the March 2026 data safety monitoring board review

> “completed a safety review of the ongoing Phase 3 ABTECT-UC maintenance trial and reported no new safety signals.”
> “Nearly 90% of enrolled participants have completed the 44-week treatment period.”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

<a id="heading-3.1.3.8.2"></a>

#### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

##### Part 1 baseline characteristics by group

| Characteristic | Placebo | Obefazimod 25 mg | Obefazimod 50 mg |
| --- | --- | --- | --- |
| Study participants | “192” | “193” | “195” |
| Age (years), mean (SD) | “41.3 (13.4)” | “43.0 (13.7)” | “42.3 (14.4)” |
| Induction baseline modified Mayo Score, mean (SD) | “6.9 (1.1)” | “6.7 (1.1)” | “6.9 (1.2)” |
| Duration of disease (years), mean (SD) | “8.1 (7.6)” | “8.1 (7.4)” | “7.8 (6.9)” |
| Induction baseline fecal calprotectin (mg/g), median | “1,202” | “1,585” | “1,568” |
| Corticosteroid use at maintenance baseline | “35.9%” | “41.5%” | “40.5%” |
| Clinical remission at maintenance baseline | “27.1%” | “37.8%” | “32.3%” |
| Prior advanced therapy failure | “37.5%” | “39.4%” | “46.2%” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.2-2"></a>

##### Higher proportion with prior advanced therapy failure in the 50 mg group

> “50 mg cohort had a higher percentage of patients with prior advanced therapy failure relative to patients on 25 mg and placebo”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.2-3"></a>

##### Definition of prior inadequate response to advanced therapy

> “AT-IR defined as: inadequate response, loss of response or intolerance to advanced therapies including biologics, JAKs, S1Ps with no upper limit”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="heading-3.1.3.8.3"></a>

#### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

##### Part 1 primary and key secondary endpoints at Week 44

| Endpoint at Week 44 | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) | Difference, 25 mg | Difference, 50 mg | P value (both doses) |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical remission, n (%) | “20 (10.4%)” | “98 (50.8%)” | “100 (51.3%)” | “∆39.3%” | “∆40.3%” | “<0.0001” |
| Endoscopic improvement, n (%) | “24 (12.5%)” | “106 (54.9%)” | “125 (64.1%)” | “∆42.5%” | “∆51.0%” | “<0.0001” |
| Endoscopic remission, n (%) | “19 (9.9%)” | “80 (41.5%)” | “93 (47.7%)” | “∆31.4%” | “∆37.8%” | “<0.0001” |
| HEMI, n (%) | “20 (10.4%)” | “97 (50.3%)” | “112 (57.4%)” | “∆39.4%” | “∆46.5%” | “<0.0001” |
| Corticosteroid-free clinical remission, n (%) | “19 (9.9%)” | “87 (45.1%)” | “93 (47.7%)” | “∆35.1%” | “∆38.0%” | “<0.0001” |
| Sustained clinical remission, n/N (%) | “8/51 (15.7%)” | “49/73 (67.1%)” | “40/61 (65.6%)” | “∆52.8%” | “∆49.1%” | “<0.0001” |

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.3-2"></a>

##### Placebo clinical remission rate of 10.4% as characterized by the company

> “The trial also recorded a 10.4% placebo clinical remission rate, the lowest reported to date in a Phase 3 UC maintenance responder re-randomization trial.”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.3-3"></a>

##### Week 52 reporting at UEG Week 2026: the same results expressed as 52 weeks of treatment overall

> “Week 52 includes the 8-week induction treatment with obefazimod”
> “Both obefazimod doses met the primary endpoint of clinical remission at Week 52 with 50.8% and 51.3% of patients receiving 25 mg and 50 mg, respectively, versus 10.4% receiving placebo (adjusted differences, 39.3 and 40.3 percentage points; both p<0.0001)”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.3-4"></a>

##### Other secondary endpoints at Week 52: clinical response and symptomatic remission

| Endpoint at Week 52 | Placebo, n/N | Placebo, % | Obefazimod 25 mg, n/N | Obefazimod 25 mg, % | Obefazimod 50 mg, n/N | Obefazimod 50 mg, % | Difference, 25 mg | Difference, 50 mg |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Clinical response | “51/192” | “26.6%” | “135/193” | “69.9%” | “147/195” | “75.4%” | “∆ 42.8%” | “∆ 49.7%” |
| Symptomatic remission | “44/192” | “22.9%” | “129/193” | “66.8%” | “128/195” | “65.6%” | “∆ 42.5%” | “∆ 41.0%” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “At Week 52, Higher Proportions of Patients Achieved Clinical Response and Symptomatic Remission With Both Obefazimod Doses than With Placebo”
> “defined as RBS=0, SFS <1”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.3-5"></a>

##### Clinical endpoints at Week 52 by prior inadequate response to advanced therapy

| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No prior AT-IR: clinical remission | “15/120” | “72/117” | “62/105” | “∆ 48%” | “p<0.0001” | “∆ 45%” | “p<0.0001” |
| No prior AT-IR: corticosteroid-free clinical remission | “15/120” | “64/117” | “59/105” | “∆ 42%” | “p<0.0001” | “∆ 43%” | “p<0.0001” |
| No prior AT-IR: sustained clinical remission | “5/38” | “42/58” | “27/38” | “∆ 62%” | “p<0.0001” | “∆ 55%” | “p=0.0003” |
| Prior AT-IR: clinical remission | “5/72” | “26/76” | “38/90” | “∆ 28%” | “p<0.0001” | “∆ 33%” | “p<0.0001” |
| Prior AT-IR: corticosteroid-free clinical remission | “4/72” | “23/76” | “34/90” | “∆ 26%” | “p=0.0001” | “∆ 31%” | “p<0.0001” |
| Prior AT-IR: sustained clinical remission | “3/13” | “7/15” | “13/23” | “∆ 24%” | “p=0.6873” | “∆ 30%” | “p=0.0915” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-6"></a>

##### Endoscopic and histologic-endoscopic endpoints at Week 52 by prior inadequate response to advanced therapy

| Subgroup and endpoint | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N |
| --- | --- | --- | --- |
| No prior AT-IR: endoscopic improvement | “18/120” | “77/117” | “77/105” |
| No prior AT-IR: endoscopic remission | “15/120” | “62/117” | “58/105” |
| No prior AT-IR: HEMI | “15/120” | “71/117” | “68/105” |
| Prior AT-IR: endoscopic improvement | “6/72” | “29/76” | “48/90” |
| Prior AT-IR: endoscopic remission | “4/72” | “18/76” | “35/90” |
| Prior AT-IR: HEMI | “5/72” | “26/76” | “44/90” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-7"></a>

##### Clinical remission at Week 52 by number of prior advanced therapies with inadequate response and after JAK inhibitor failure

| Subgroup | Placebo, n/N | Obefazimod 25 mg, n/N | Obefazimod 50 mg, n/N | Difference, 25 mg | P value, 25 mg | Difference, 50 mg | P value, 50 mg |
| --- | --- | --- | --- | --- | --- | --- | --- |
| No prior AT-IR | “15/120” | “72/117” | “62/105” | “∆ 49%” | “p<0.0001” | “∆ 47%” | “p<0.0001” |
| One prior AT-IR | “4/27” | “12/31” | “17/41” | “∆ 24%” | “p=0.2785” | “∆ 27%” | “p=0.0584” |
| Two prior AT-IR | “0/24” | “7/22” | “8/19” | “∆ 32%” | “p=0.0215” | “∆ 42%” | “p=0.0014” |
| Three prior AT-IR | “1/12” | “4/12” | “10/21” | “∆ 25%” | “p=0.0771” | “∆ 39%” | “p=0.0968” |
| Four or more prior AT-IR | “0/9” | “3/11” | “3/9” | “∆ 27%” | “NC” | “∆ 33%” | “p=0.1967” |
| Prior JAK inhibitor inadequate response | “0/16” | “4/14” | “5/15” | “∆ 29%” | “p=0.0190” | “∆ 33%” | “p=0.0375” |

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-8"></a>

##### Conclusions of the subgroup presentation

> “Treatment differences favored obefazimod over placebo across clinical, endoscopic, symptomatic, and histologic-endoscopic outcomes in AT-IR naïve and in with patients with prior ATIR”
> “Placebo-adjusted treatment differences were generally numerically larger in AT-IR naïve vs. with patients with prior ATIR”
> “Clinical remission rates numerically favored both obefazimod doses across 0 to ≥4 prior AT-IR therapies and in JAK-IR patients”

Source: [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf)

<a id="topic-3.1.3.8.3-9"></a>

##### Part 2: induction non-responders continuing obefazimod, exploratory endpoints at Week 44

| Endpoint | Obefazimod 25 mg (N=81) | Obefazimod 50 mg (N=148) |
| --- | --- | --- |
| Clinical remission | “23.5%” | “37.2%” |
| Clinical response | “50.6%” | “61.5%” |
| Endoscopic improvement | “28.4%” | “48.0%” |
| HEMI | “23.5%” | “44.6%” |
| Endoscopic remission | “22.2%” | “34.5%” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.3-10"></a>

##### Part 2: Part 1 relapsers re-treated with obefazimod 50 mg, exploratory endpoints at Week 44

| Endpoint | Placebo in Part 1, then 50 mg (N=109) | Obefazimod 25 mg in Part 1, then 50 mg (N=33) |
| --- | --- | --- |
| Clinical remission | “45.0%” | “45.5%” |
| Clinical response | “69.7%” | “66.7%” |
| Endoscopic improvement | “54.1%” | “45.5%” |
| HEMI | “47.7%” | “39.4%” |
| Endoscopic remission | “32.1%” | “24.2%” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.3-11"></a>

##### No results posted in the registries

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946)

> “Summary of the results: not applicable: the trial has not ended.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.8.4"></a>

#### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.3.8.4-1"></a>

##### IBDQ response: long-term extension endpoint in the EU register, no results reported

> “Long-Term Extension (LTE) (4 years): Proportion of subjects with IBDQ response by visit.”

Source: [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01)

<a id="heading-3.1.3.8.5"></a>

#### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

##### Part 1 treatment-emergent adverse events over 44 weeks

| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
| --- | --- | --- | --- |
| Any TEAE | “96 (50.0%)” | “112 (58.0%)” | “140 (71.8%)” |
| TEAE leading to study drug discontinuation | “13 (6.8%)” | “5 (2.6%)” | “9 (4.6%)” |
| Serious TEAE | “8 (4.2%)” | “5 (2.6%)” | “11 (5.6%)” |
| Death | “0” | “0” | “0” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “2 (1.0%)” | “2 (1.0%)” | “1 (0.5%)” |
| Acute pancreatitis | “0” | “0” | “0” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” | “0” |
| Malignancy other than NMSC: prostate cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: breast cancer | “0” | “0” | “1 (0.5%)” |
| Malignancy other than NMSC: colonic dysplasia | “0” | “0” | “1 (0.5%)” |
| NMSC: basal cell carcinoma | “1 (0.5%)” | “0” | “2 (1.1%)” |
| NMSC: squamous cell carcinoma | “0” | “1 (0.5%)” | “2 (1.1%)” |

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.5-2"></a>

##### Part 1 malignancies and non-melanoma skin cancers as described by the company

> “Non-NMSC: The prostate, breast, and colon cancer cases were considered unrelated to treatment by investigators, and no organ-specific clustering was observed”
> “Two of the four 50 mg patients were deemed not/unlikely related to drug by investigators; of the remaining two cases, one had a medical history of skin cancer”
> “The mean age of observed NMSC cases was 62 years, compared with 42 years in the overall trial population, consistent with age-related NMSC risk”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.5-3"></a>

##### Part 1 serious or severe infections by group

> “Serious/Severe Infections and Opportunistic Infections: Placebo = Anal abscess, bronchitis & gastroenteritis, 25 mg = 1 Lymph node tuberculosis, 1 tonsillitis, 50 mg = 1 Appendicitis, focal peritonitis”

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="topic-3.1.3.8.5-4"></a>

##### Part 1 related serious adverse events, pregnancies, and colonic dysplasia as presented at UEG Week 2026

| Event, n (%) | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
| --- | --- | --- | --- |
| Patients with any related serious TEAE | “1 (0.5%)” | “0” | “0” |
| Pregnancy | “0” | “0” | “2 (1.1%)” |

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

> “One case of colonic dysplasia was reported in the obefazimod 50mg arm.”
> “No cases of acute pancreatitis were reported”
> “Overall favorable safety profile with no evidence of immunosuppression, consistent with the proposed mechanism of action of restoring immune balance while maintaining key components of immune surveillance”

Source: [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf)

<a id="topic-3.1.3.8.5-5"></a>

##### Part 2 treatment-emergent adverse events in induction non-responders and Part 1 relapsers

| Event, n (%) | Obefazimod 25 mg (N=186) | Obefazimod 50 mg (N=447) |
| --- | --- | --- |
| Any TEAE | “132 (71.0%)” | “307 (68.7%)” |
| TEAE leading to study drug discontinuation | “21 (11.3%)” | “27 (6.0%)” |
| Serious TEAE | “16 (8.6%)” | “23 (5.1%)” |
| Death, not treatment related | “1 (0.5%)” | “0” |
| Pregnancy | “1 (0.5%)” | “1 (0.2%)” |
| Serious or severe (grade 3 or higher) infections and opportunistic infections | “5 (2.7%)” | “5 (1.1%)” |
| Malignancies excluding NMSC | “0” | “2 (0.4%)” |
| NMSC | “2 (1.1%)” | “2 (0.4%)” |
| Acute pancreatitis | “1 (0.5%)” | “1 (0.2%)” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” |

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="topic-3.1.3.8.5-6"></a>

##### Part 2 death, infections, and malignancies: footnotes to the safety table

> “One death occurred in the 25 mg arm and was assessed by the investigator as unrelated to obefazimod. The suspected cause was pulmonary embolism in a 65+ patient with multiple pre-existing thromboembolic risk factors, including prior pulmonary embolism, and recent prolonged immobility.”
> “Serious/severe (grade ≥3) infections and opportunistic infections: 25 mg = Appendicitis, Bartonellosis, Cytomegalovirus gastrointestinal infection, Peritonsillar abscess, Sepsis; 50 mg (induction non-responder) = Clostridium difficile infection, pilonidal disease, Urethritis gonococcal; 50 mg Open Label (Part 1 relapsers = Appendicitis (Part 1 50 mg), Septic arthritis staphylococcal (Part 1 placebo).”
> “Part 1 relapsers previous on placebo: One case of Myoproliferative Neoplasm and one Prostate Cancer.”
> “Two cases of Basal Cell Carcinoma (25 mg | 50 mg) and two cases of Squamous Cell Carcinoma (25 mg | 50 mg).”

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="topic-3.1.3.8.5-7"></a>

##### Part 2 malignancies and non-melanoma skin cancers: case characteristics and investigator assessment

| Case | Dose | Exposure to obefazimod | Age | Thiopurine history | Medical history of cancer or skin cancer | Investigator assessment |
| --- | --- | --- | --- | --- | --- | --- |
| Myeloproliferative neoplasm | “50 mg” | “7.4 months” | “40+” | “No” | “No” | “Determined not related to study drug by investigator” |
| Prostate cancer | “50 mg” | “3.4 months” | “55+” | “Yes azathioprine” | “No” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “50 mg” | “10.4 months” | “40+” | “Yes azathioprine” | “No” | “Determined probably related to study drug by investigator” |
| Squamous cell carcinoma | “50 mg” | “4.6 months” | “55+” | “Yes azathioprine” | “Yes” | “Determined not related to study drug by investigator” |
| Basal cell carcinoma | “25 mg” | “8.1 months” | “50+” | “Yes azathioprine” | “No” | “Determined unlikely related to study drug by investigator” |
| Squamous cell carcinoma | “25 mg” | “8.3 months” | “75+” | “No” | “Yes” | “Determined probably related to study drug by investigator” |

Source: [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm)

<a id="topic-3.1.3.8.5-8"></a>

##### Part 2 malignancies and non-melanoma skin cancers as described by the company

> “In Part 2, four total NMSC events were reported, two in the 25 mg arm and two in the 50 mg arm, which all occurred in patients with established NMSC risk factors including advanced age, thiopurine use, prior skin cancer history and failure of multiple prior advanced therapies. There were also two non-NMSC malignancies reported in the 50 mg arm, both deemed unrelated to obefazimod by the study investigators.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-9"></a>

##### Exposure-adjusted incidence of malignancies excluding NMSC (post-hoc), with the company's expected background range

| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
| --- | --- | --- | --- | --- | --- |
| Integrated UC program (phase 2 and phase 3) | “0.00” | “0.00” | “0.64” | “0.35” | “0.30 – 0.70” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.00” | “0.00” | “0.91” | “0.56” | “0.30 – 0.70” |
| Part 2 only | “-” | “0.00” | “0.69” | “0.48” | “0.30 – 0.70” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-10"></a>

##### Exposure-adjusted incidence of non-melanoma skin cancer (post-hoc), with the company's expected background range

| Analysis set | Placebo, IR/100 PY | 25 mg, IR/100 PY | 50 mg, IR/100 PY | All active, IR/100 PY | Expected UC background |
| --- | --- | --- | --- | --- | --- |
| Integrated UC program (phase 2 and phase 3) | “0.46” | “0.53” | “0.64” | “0.59” | “0.70 – 1.40” |
| Phase 3 maintenance (Part 1 and Part 2) | “0.68” | “1.09” | “1.37” | “1.26” | “0.70 – 1.40” |
| Part 2 only | “-” | “1.52” | “0.69” | “0.95” | “0.70 – 1.40” |

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-11"></a>

##### Company interpretation of the exposure-adjusted malignancy analyses

> “Across the integrated Phase 2 and Phase 3 UC program (1,704 patient-years of exposure), exposure-adjusted incidence rates”
> “Because NMSCs and malignancies excluding NMSCs are uncommon events, incidence-rate estimates become more precise as cumulative exposure increases. The ABTECT Maintenance data should be interpreted using the totality of the exposure-adjusted evidence, together with patient characteristics and representative published UC epidemiologic reference ranges.”
> “The results in the tables below demonstrate that the exposure-adjusted incidence rate in the combined all active (25 mg + 50 mg) treatment arms for both NMSCs and malignancies excluding NMSCs are within the UC background reference range based on published UC studies.”
> “The overall safety results observed in Part 2 were consistent with those previously observed in the broader obefazimod clinical development program. No new safety pattern emerged with the additional cumulative exposure provided by Part 2.”

Source: [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results)

<a id="topic-3.1.3.8.5-12"></a>

##### Interim data safety monitoring board reviews in December 2025 and March 2026

> “ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trial”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

> “ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of patients randomized, with nearly 90% having completed the 44-week double blind maintenance trial”

Source: [Abivax full year 2025 results announcement (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-full-year-2025-financial-results-and-provides)

<a id="topic-3.1.3.8.5-13"></a>

##### Acute pancreatitis and cardiac abnormalities suggestive of cardiac fibrosis: ABTECT maintenance Part 1

| Event | Placebo (N=192) | Obefazimod 25 mg (N=193) | Obefazimod 50 mg (N=195) |
| --- | --- | --- | --- |
| Acute pancreatitis | “0” | “0” | “0” |
| Cardiac abnormalities suggestive of cardiac fibrosis | “0” | “0” | “0” |

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial)

<a id="heading-3.1.3.9"></a>

### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

#### Summary

As of November 2026, the results of ABTECT Maintenance come only from company press releases of June 1 and June 29, 2026, a prospectus supplement, and two slide presentations at UEG Week 2026. No peer-reviewed publication exists, the ClinicalTrials.gov record shows “No Results Posted”, and the EU register states that the trial has not ended; no protocol or statistical analysis plan for this trial is posted on ClinicalTrials.gov. The long-term extension continues to an estimated study completion in May 2030.

Part 1 is a randomized withdrawal design. Its 580 analyzed participants (192 placebo, 193 obefazimod 25 mg, 195 obefazimod 50 mg) had all responded to 8 weeks of obefazimod induction, so the placebo group measures withdrawal of obefazimod after an initial response; participants without an induction response are reported separately in Part 2. Of the 678 induction responders who entered Part 1, placebo induction responders were kept on blinded placebo and are outside the 580-participant comparison. Completion of Week 44 without relapse or treatment switch was 66 of 192 (34.3%) with placebo, against 152 of 193 (78.8%) and 160 of 195 (82.1%) with obefazimod 25 mg and 50 mg, so most placebo participants left the randomized treatment before Week 44; the handling of these participants in the efficacy analysis has not been published.

The timepoint is reported as Week 44 in the press releases and registry and as “Week 52” in the UEG Week slides, which count the 8-week induction. The registries differ: ClinicalTrials.gov names clinical remission at Week 44 as the Part 1 primary endpoint, while the EU register states the Part 1 objective as comparing obefazimod with placebo on “endoscopic improvement and symptomatic remission” and lists clinical remission at Week 44 among the Part 1 endpoints. Symptomatic remission (66.8% and 65.6% with obefazimod against 22.9% with placebo) is reported only in the slides, and its printed definition reads “RBS=0, SFS <1”. Corticosteroid-free clinical remission is registered in the subpopulation receiving corticosteroids at maintenance entry, while the reported counts (19 of 192, 87 of 193, and 93 of 195) use all randomized participants as the denominator.

Prior advanced therapy failure was more frequent in the 50 mg group (46.2%) than in the 25 mg (39.4%) and placebo (37.5%) groups. Placebo-adjusted differences were numerically smaller in participants with prior inadequate response to advanced therapy (clinical remission differences of 28% and 33%) than in those without (48% and 45%). The subgroup analyses by number of prior advanced therapies and after JAK inhibitor failure involved 9 to 41 participants per group, and their differences are unadjusted with nominal p-values that the presenters describe as “descriptive rather than confirmatory”; the sustained clinical remission subgroup with prior advanced therapy failure included 13, 15, and 23 participants.

Part 2 efficacy results come from groups without a placebo comparator: induction non-responders who continued obefazimod (81 on 25 mg and 148 on 50 mg) and Part 1 relapsers re-treated with open-label 50 mg (109 previously on placebo and 33 previously on 25 mg). The company labels these results exploratory and the integrated safety analyses post-hoc.

Malignancy findings rest on small numbers of events. In Part 1, the 50 mg group had one prostate cancer, one breast cancer, and one colonic dysplasia, listed by the release under malignancies other than NMSC, and four NMSC (two basal cell and two squamous cell carcinomas), against one NMSC with placebo and one with 25 mg; no malignancy other than NMSC occurred with placebo or 25 mg. Part 2 added two malignancies excluding NMSC (a myeloproliferative neoplasm and a prostate cancer, both in Part 1 placebo relapsers re-treated with 50 mg) and four NMSC, two of which the investigators judged probably related to study drug. In the phase 3 maintenance dataset, the exposure-adjusted incidence of NMSC was 1.37 per 100 patient-years with 50 mg and 0.68 with placebo, and of malignancies excluding NMSC 0.91 with 50 mg and 0.00 with placebo. The company's comparison of these rates with a “UC background reference range” is post-hoc and compares the trial's rates with an external reference range from published studies. Part 2 also reported one death from suspected pulmonary embolism, assessed as unrelated, and one case of acute pancreatitis in each dose group, an event with no cases in Part 1.

Source: [Abivax press release, ABTECT maintenance results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-landmark-phase-3-abtect-maintenance-trial); [Abivax press release, ABTECT maintenance Part 2 results (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-reports-positive-abtect-maintenance-part-2-results); [Abivax prospectus supplement (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm); [Sands et al. (2026a)](https://www.abivax.com/wp-content/uploads/2026/10/OP097-ABTECT-Topline-OP-DRAFT-07OCT2026-Sands-UEGW2026-ABVX-Obe-1.pdf); [Danese et al. (2026)](https://www.abivax.com/wp-content/uploads/2026/10/OP260-ABTECT-ATIR-19OCT2026-Danese-UEGW2026.pdf); [ClinicalTrials.gov NCT05535946](https://clinicaltrials.gov/study/NCT05535946); [CTIS.eu 2022-500537-84-01](https://ctis.eu/trial/2022-500537-84-01); [Abivax press release, ABTECT induction results (2025)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-phase-3-results-both-abtect-8-week)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
